Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Goodwill & Intangibles (2022 - 2025)

Axsome Therapeutics' Goodwill & Intangibles history spans 4 years, with the latest figure at $12.0 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 84.12% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $12.0 million, down 84.12%, while the annual FY2025 figure was $12.0 million, 84.12% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $12.0 million at Axsome Therapeutics, roughly flat from $12.0 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $75.8 million in Q4 2024 and bottomed at $10.3 million in Q1 2023.
  • The 4-year median for Goodwill & Intangibles is $65.3 million (2023), against an average of $47.8 million.
  • The largest YoY upside for Goodwill & Intangibles was 529.81% in 2025 against a maximum downside of 84.12% in 2025.
  • A 4-year view of Goodwill & Intangibles shows it stood at $70.0 million in 2022, then dropped by 6.64% to $65.3 million in 2023, then rose by 16.09% to $75.8 million in 2024, then tumbled by 84.12% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Goodwill & Intangibles are $12.0 million (Q4 2025), $12.0 million (Q3 2025), and $75.8 million (Q2 2025).